May 5, 2020 / 9:41 PM / a month ago

BRIEF-Spero Completes Patient Enrollment In Phase 3 Clinical Trial Of Oral Tebipenem Hbr Versus Intravenous Ertapenem For Treatment Of Complicated Urinary Tract Infection

May 5 (Reuters) - Spero Therapeutics Inc:

* SPERO THERAPEUTICS COMPLETES PATIENT ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL (ADAPT-PO) OF ORAL TEBIPENEM HBR VERSUS INTRAVENOUS ERTAPENEM FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below